SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Wyeth has reported results for second quarter ended September 30, 2012.    

The company’s net profit for the quarter declined by 10.90% at Rs 30.25 crore as compared to Rs 33.95 crore for the same quarter in the previous year. Total income of the company has increased by 5.35% at Rs 157.14 crore for quarter under review as compared to Rs 149.16 crore for the quarter ended September 30, 2011.

Wyeth is the Indian subsidiary of US-based Pharma Company Wyeth, a global leader in pharmaceutical, consumer healthcare and animal health products. The pharmaceuticals business of the company comprises bulk drugs and formulations, such as oral contraceptives, hormone replacement therapy, antibiotics, vaccines, steroids and other prescription medicines. The company also manufactures OTC pharmaceuticals, cosmetics, toiletries and other allied consumer products.

Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1279.70
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2245.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×